论文部分内容阅读
目的制备树突状细胞(dendritic cells,DC)与胶质瘤融合细胞,探讨其特异性抗肿瘤活性。方法诱导正常人外周血来源DC,在PEG作用下将其与胶质瘤细胞BT325融合,通过双荧光标记法检测融合率、MTT法测定CTL活性。结果融合细胞在培养体系中占较高比例;DC/胶质瘤融合细胞激活的CTLs对胶质瘤的杀伤作用显著高于DC与胶质瘤细胞联合培养DC组(P<0.05)及其他对照组,而且杀伤活性随着效靶比的增加而增加。结论DC与胶质瘤细胞融合是一种更为有效的以DC为基础的抗肿瘤策略。
Objective To prepare dendritic cells (DCs) and glioma-fused cells and investigate their specific anti-tumor activity. Methods DCs from normal human peripheral blood were induced to fuse with glioma cells BT325 under the action of PEG. The fusion rate was detected by double fluorescent labeling and the activity of CTL was determined by MTT assay. Results The percentage of CTLs in DC / glioma fusion cells was significantly higher than that in glioma cells co-cultured with DC and glioma cells (P <0.05) and other control Group, and the killing activity increased with the increase of effective target ratio. Conclusion Fusion of DC with glioma cells is a more effective DC-based antitumor strategy.